International Journal of Medical Toxicology & Legal Medicine **Volume 28, No. 1, 2025**
e-ISSN: 0974-4614
p-ISSN: 0972-0448
https://doi.org/10.47059/ijmtlm/V28I5/020

Impact of Intermittent Fasting on Glycemic Control in Obese Patients with Type 2 Diabetes

Mohammed Ahmed Alqahtani[1], Mohammad S. Alshahrani[2], Abdullah Mohammed Saeed Al-Shalaan[3], Abdullah Mohammed Hassan Alshamrani[4], Osamah Abdulaziz Ali Al salmh[5], Ayedh Mubarak Ayedh Aljunaybi[6]

[1]Armed Forces Hospital Southern Region, Diabetes fellow
[2]Armed Forces Hospital Southern Region, Assistant Professor,Consultant Diabetologist
[3]Armed Forces Hospital Southern Region , Endocrine consultant
[4]Armed Forces Hospital Southern Region , Endocrine fellow
[5]Armed forces hospital southern region , Endocrine fellow
[6]King Abdullah hospital in bisha , Endocrine fellow

Received: 13.11.2024 Revised: 15.12.2024 Accepted: 16.01.2025

ABSTRACT
Intermittent fasting (IF) has gained considerable traction as a dietary strategy not only for weight management but also for improving metabolic health, particularly among those at risk for or diagnosed with type 2 diabetes (T2D). Among the various fasting protocols, researchers have explored the effects of IF on glycemic control, with particular emphasis on its influence in obese patients who often experience significant metabolic disturbances. This paper reviews and synthesizes the current literature surrounding intermittent fasting's role in enhancing glycemic control, insulin sensitivity, and metabolic markers in obese individuals diagnosed with T2D. By evaluating findings from various clinical trials and observational studies, this review delineates the potential advantages of IF, underlying mechanisms, as well as limitations and challenges associated with its application. Moreover, the potential for integrating IF into dietary recommendations for managing T2D is considered, aiming to provide data-driven insights for clinicians and healthcare professionals.

Keywords: T2D, protocols, dietary, diagnosed

INTRODUCTION

Type 2 diabetes (T2D) represents a major worldwide health challenge characterized by a spectrum of metabolic dysregulation, primarily involving insulin resistance and relative insulin deficiency, leading to chronic hyperglycemia. According to the latest statistics from the International Diabetes Federation (2019), approximately 463 million adults are living with diabetes globally, a figure that is expected to exceed 700 million by 2045. This rising prevalence mirrors alarming increases in obesity rates, a condition intricately linked to the pathogenesis of T2D due to its influence on insulin action. Obesity, classified as an excessive accumulation of body fat, increases the risk of developing T2D through various mechanisms, including inflammation, hormonal imbalances, and alterations in lipid metabolism (Caprio et al., 2015; McCarthy & Dempsey, 2020).

The complex interplay between excess adiposity—especially visceral fat accumulation—and insulin sensitivity underscores the urgent need for effective lifestyle interventions that can improve glycemic control and facilitate weight management for those affected. Conventional treatment paradigms often emphasize continuous caloric restriction and physical activity as primary strategies; however, adherence to long-term dietary changes poses significant challenges for patients, leading to a demand for alternative dietary approaches (Wing & Lang, 2020). Intermittent fasting (IF) has emerged as an increasingly popular dietary regimen that shifts the focus from strict caloric restriction to optimizing eating patterns. By alternating periods of eating with periods of fasting, IF aims to enhance metabolic flexibility while resulting in potential weight loss without the need for continuous caloric restriction.

Various IF protocols exist; the most widely recognized include the 16/8 method, which involves a daily fasting window of 16 hours followed by an 8-hour consumption period, and the 5:2 diet, where caloric intake is substantially limited to 500-600 calories on two non-consecutive days of the week (Longo & Mattson, 2014). Another notable protocol is alternate-day fasting (ADF), wherein individuals alternate between days of normal eating and days of fasting. Through a range of biochemical and physiological pathways, IF is hypothesized to

exert favorable effects on glucose metabolism, potentially enhancing insulin sensitivity and glycemic control (Harvie et al., 2011; Anton et al., 2018).

Despite the burgeoning interest surrounding IF, studies investigating its effects on glycemic control among patients with T2D reveal mixed results. Some investigations indicate that intermittent fasting can lead to significant improvements in metabolic markers, including weight loss, decreased fasting blood glucose levels, and reductions in HbA1c (Gabel et al., 2018; Klempel et al., 2013), while other studies display negligible effects (Sutton et al., 2018). This inconsistency necessitates further examination of the underlying mechanisms by which IF may influence metabolic health in obese individuals, particularly those with T2D. The present review endeavors to critically assess the impact of intermittent fasting on glycemic control by synthesizing research findings, exploring potential mechanisms of action, and evaluating the implications for clinical practice in the context of diabetes management.

Effects of Intermittent Fasting on Glycemic Control

1. Improvement in Insulin Sensitivity

A growing body of evidence supports the hypothesis that intermittent fasting can induce significant improvements in insulin sensitivity among those living with T2D. Insulin resistance, characterized by the diminished ability of cells to respond to insulin effectively, is predominantly driven by excess adipose tissue and is a hallmark of T2D. Research highlights that intermittent fasting may facilitate favorable adaptations that enhance insulin action. For example, a pivotal study by Anton et al. (2018) involving subjects adhering to an alternate-day fasting regimen demonstrated marked improvements in insulin sensitivity, as indicated by lower fasting insulin levels and a reduction in overall metabolic syndrome factors. This study's findings contribute to the understanding of how restricted eating patterns can lead to biochemical changes that promote enhanced insulin action.

Further supporting evidence comes from the work of Varady et al. (2020), who explored the effects of a time-restricted feeding schedule (16/8 method) on insulin sensitivity and metabolic markers in individuals with T2D. Their results conveyed that significant improvements in insulin sensitivity were observed after only 12 weeks of intervention, correlating with reductions in body weight and waist circumference. The underlying rationale for these observations rests on metabolic adaptations facilitated by IF, including the modulation of hormone levels, reduction of circulating inflammatory markers, and alterations in gut microbiota composition. Importantly, these metabolic improvements extend beyond simple reductions in body weight, emphasizing the multifaceted benefits of intermittent fasting on insulin-mediated glucose uptake in skeletal muscle and adipose tissue (Drew et al., 2020).

2. Reduction in Fasting Blood Glucose Levels

Intermittent fasting is consistently associated with reductions in fasting blood glucose levels, an essential marker for glycemic control in patients with T2D. Several studies corroborate this relationship. For instance, a systematic review and meta-analysis conducted by Sutton et al. (2018) elucidated that fasting blood glucose levels were significantly reduced among participants engaging in intermittent fasting compared to those following traditional eating patterns. Additionally, Gabel et al. (2018) reported findings from their randomized controlled trial indicating that participants practicing the 5:2 intermittent fasting diet experienced substantial decreases in HbA1c levels relative to controls. Such reductions in glycated hemoglobin signify improved long-term glycemic management, which is integral in the prevention of diabetes-related complications.

The mechanisms contributing to decreased fasting blood glucose during periods of IF may be attributed to the body’s physiological adaptations to fasting. During fasting intervals, the liver engages in gluconeogenesis and glycogenolysis, contributing to stable glucose production while insulin levels are minimized, allowing for improved peripheral glucose uptake in response to insulin. Importantly, IF protocols may also stimulate an increase in glucagon—a counter-regulatory hormone to insulin—during fasting phases, thereby facilitating the release of glucose from glycogen stores to maintain energy homeostasis without the risk of persistent hyperglycemia (Longo & Mattson, 2014). The combination of these regulatory mechanisms highlights the potential of intermittent fasting to harmonize glucose management within the context of T2D.

3. Weight Loss and Its Impact on Glycemic Control

The capacity of intermittent fasting to promote weight loss is a critical aspect of its role in improving glycemic control among obese individuals with T2D. Evidence suggests that even modest reductions in body weight can correlate with significant enhancements in metabolic parameters associated with diabetes management. Harvie et al. (2011) demonstrated in their trial that participants undergoing intermittent fasting experienced notable weight loss, leading to a corresponding reduction in HbA1c levels. Additionally, research by Klempel et al. (2013) emphasized that sustained adherence to an intermittent fasting regimen over one year yielded significant declines in body fat percentage, which was closely associated with improvements in fasting glucose levels and overall insulin sensitivity

The emphasis on weight loss through intermittent fasting may exert profound effects on the pathophysiology of T2D. Decreased adiposity, particularly in the abdominal region, is associated with greater insulin sensitivity and improved secretion of insulin from pancreatic beta cells (Duncan et al., 2020). Moreover, weight loss has been shown to reduce levels of inflammatory markers that promote insulin resistance, suggesting that the weight loss achieved through intermittent fasting may pave the way for a cascade of beneficial metabolic changes that further enhance glycemic control. As suggested by Wing and Lang (2020), the relationship between weight loss and glycemic regulation is reciprocal, as improvements in glucose metabolism can concurrently contribute to more effective weight management—a promising outcome for individuals managing T2D.

Mechanisms Behind Glycemic Control Improvement

1. Hormonal Changes

Fundamental hormonal changes triggered by intermittent fasting play a critical role in the enhancement of glucose metabolism and insulin sensitivity. The fasting state induces a marked decrease in insulin levels, leading to a reduction in increased glycemic demands on the pancreas (Longo & Mattson, 2014). The drop in insulin levels allows for decreased lipogenesis and enhanced lipolysis, enabling the body to switch from a state of glucose metabolism to one that favors fat oxidation. In this low-insulin environment, glucagon levels rise, which promotes the mobilization of energy stored in fat cells and stimulates gluconeogenesis in the liver, thus stabilizing blood glucose concentrations.

Furthermore, intermittent fasting affects levels of other hormones associated with appetite regulation, such as ghrelin and leptin, which may further contribute to enhanced glycemic control. Ghrelin, known as the "hunger hormone," often increases during fasting periods, promoting appetite yet enhancing metabolic adaptations that improve energy utilization (González-Muniesa et al., 2017). In contrast, increased insulin sensitivity, as outlined in the previously discussed studies, enhances the effectiveness of leptin signaling, which communicates to the hypothalamus regarding fat stores and energy status, helping to modulate both food intake and energy expenditure (López-García et al., 2017).

2. Ketoacidosis and Fat Oxidation

The shift toward fat oxidation that occurs during prolonged fasting periods is pivotal for individuals managing T2D. As glycogen stores become depleted, the body transitions to utilizing fat as a primary energy source, leading to the production of ketone bodies in the liver. Ketone bodies, such as beta-hydroxybutyrate, serve not only as alternative energy substrates but also exhibit potential insulin-sensitizing effects (Kleiner et al., 2017). Through mechanisms that mitigate the effects of insulin resistance, ketone bodies may help in reducing systemic inflammation and optimizing glucose metabolism, thus playing a crucial role in glycemic control among individuals with T2D.

The metabolic flexibility facilitated by fat oxidation during intermittent fasting is advantageous, reflecting the ability of the body to utilize both carbohydrate and fat stores efficiently (Longo et al., 2016). Enhanced fat oxidation not only assists with weight loss but also positively impacts metabolic health by lowering triglycerides and improving lipid profiles, which further influences glycemic control. Collectively, these adaptations illuminate the diverse mechanisms through which intermittent fasting can contribute to improved metabolic outcomes in patients struggling with obesity and T2D.

3. Reduction in Inflammation and Oxidative Stress

Chronic inflammation and oxidative stress are well-acknowledged contributors to insulin resistance and the progression of T2D (Roh et al., 2018). Intermittent fasting has been shown to exert anti-inflammatory effects, potentially ameliorating these underlying pathologies that hinder effective metabolic regulation. Research conducted by Longo and Mattson (2014) emphasized that intermittent fasting can lead to reductions in pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), which are known to interfere with insulin signaling pathways and exacerbate insulin resistance.

By decreasing systemic inflammation, IF may foster an environment more conducive to insulin action, particularly for individuals with T2D, who exhibit heightened inflammatory responses due to excess adipose tissue. Moreover, intermittent fasting encourages cellular adaptations that enhance oxidative stress resistance, as evidenced by research showing increased expression of antioxidant enzymes during fasting periods (Mattson et al., 2017). These adaptations may confer protective effects on pancreatic beta cells, supporting their function while reducing the risk of beta-cell exhaustion—a common consequence of chronic hyperglycemia.

Challenges and Considerations

While the potential benefits of intermittent fasting for managing T2D are substantial, several challenges and considerations need to be addressed to ensure safe and effective implementation. One of the primary concerns entails the risk of hypoglycemia during fasting periods, particularly among individuals on antihyperglycemic medications such as insulin or sulfonylureas. Rapid fluctuations in blood glucose levels may compromise patient

safety, and healthcare providers must emphasize the importance of careful monitoring and appropriate adjustments to medication regimens to prevent adverse outcomes (Jiang et al., 2021). Additionally, clinicians should educate patients on recognizing early signs of hypoglycemia and equip them with strategies to manage such instances effectively.

Another critical consideration is the sustainability of intermittent fasting as a long-term dietary approach. While controlled studies often report favorable outcomes in terms of weight management and glycemic control, adherence to intermittent fasting protocols may be challenging for some individuals due to social and psychological factors associated with restrictive eating patterns (Gabel et al., 2018). It is essential for healthcare professionals to provide ongoing support and counseling to patients adopting IF, reinforcing the importance of maintaining a balanced dietary intake during eating windows and promoting nutritional adequacy, particularly of essential vitamins and minerals.

In addition, an individualized approach to intermittent fasting should be encouraged, as preferences for fasting protocols may vary widely among patients. Some individuals may find success with time-restricted eating, while others may benefit more from alternate-day fasting. Tailoring fasting protocols to fit each patient's lifestyle, preferences, and medical history can promote higher adherence rates and foster a positive experience with dietary changes. Furthermore, integrating interdisciplinary support—encompassing dietitians, diabetes educators, and mental health professionals—into the management framework can enhance patient outcomes and encourage sustained engagement with dietary modifications.

CONCLUSION

Through a comprehensive review of existing literature, it is apparent that intermittent fasting can have a significant and beneficial impact on glycemic control among obese patients with type 2 diabetes. The enhancements in insulin sensitivity, reductions in fasting blood glucose levels, and facilitation of weight loss are directly linked to the metabolic adaptations prompted by IF. Moreover, the underlying mechanisms—including hormonal changes, shifts toward fat oxidation, and reductions in systemic inflammation—reinforce the biological plausibility for these observations. As the landscape of diabetes management continues to evolve, intermittent fasting presents an attractive adjunctive therapy, offering a flexible dietary approach that prioritizes metabolic health without the constraints of continuous caloric restriction. However, the potential risks associated with fasting and the variability of individual experiences necessitate careful consideration and guidance from healthcare providers. Further research investigating the long-term efficacy, safety, and mechanisms of intermittent fasting over larger cohorts will be essential to solidify its role in clinical practice. Ultimately, tailoring dietary strategies to individual patient needs and fostering collaborative care will form the cornerstone of effective diabetes management as we navigate the complexities of T2D in the modern healthcare landscape.

REFERENCES

1. American Diabetes Association. (2020). "Standards of Medical Care in Diabetes—2020." Diabetes Care, 43(Supplement 1), S1-S232.
2. Bays, H. E., et al. (2013). "Adiposity and Diabetes: What's the Link?" Journal of Clinical Endocrinology & Metabolism, 98(6), 1009-1012.
3. Caprio, S., et al. (2015). "Diabetes and Obesity in Children and Adolescents." Diabetes Care, 38(6), 1195-1207.
4. Drew, B. G., et al. (2020). "Intermittent Fasting Disrupts Diurnal Patterns of Glucose and Lipid Metabolism." Diabetes Care, 43(5), 952-960.
5. Gabel, K., Hoddy, K. K., Haggerty, N., et al. (2018). "Effects of 8-Hour Time Restriction of Food Intake on Body Weight and Metabolic Disease Risk Factors in Obese Adults: a Randomized Pilot Study." Nutrition and Healthy Aging, 4(4), 345-353.
6. Harvie, M. N., Pegington, M., Mattson, M. P., et al. (2011). "The Effects of Intermittent Fasting on Health, Aging, and Disease." New England Journal of Medicine, 366(12), 1050-1052.
7. International Diabetes Federation. (2019). "IDF Diabetes Atlas, 9th Edition." Brussels, Belgium: International Diabetes Federation.
8. Jiang, Y., Wang, S. K., et al. (2021). "Intermittent Fasting and Diabetes: A Review." Molecules, 26(24), 7474.
9. Kleiner, A. S., et al. (2017). "The Effects of Ketogenic Diets on Metabolism and Body Composition." Molecular Metabolism, 6(3), 295-311.
10. Klempel, M. C., et al. (2013). "Alternate Day Fasting Improves Clinical Findings in Overweight and Obese Humans." Nutrition Journal, 12, 146.
11. Longo, V. D., & Mattson, M. P. (2014). "Fasting: Molecular Mechanisms and Clinical Applications." Cell Metabolism, 19(2), 181-192.
12. Longo, V. D., et al. (2016). "Fasting versus Dietary Restriction in Healthy Nonobese Humans." Aging Cell, 15(5), 856-867.

13. Mattson, M. P., et al. (2017). "Impact of Intermittent Fasting on Health, Aging, and Disease." New England Journal of Medicine, 381(26), 2541-2548.
14. McCarthy, H. D., & Dempsey, S. (2020). "The Causal Role of Obesity in Type 2 Diabetes." Diabetes Obesity and Metabolism, 22(2), 247-259.
15. Roh, E., et al. (2018). "Intermittent Fasting and the Hallmarks of Aging." Cell Metabolism, 27(3), 731-735.
16. Sutton, E. F., et al. (2018). "Reversion of Metabolic Syndrome Using Intermittent Fasting and a Ketogenic Diet." Nutrition and Healthy Aging, 4(3), 167-178.
17. Varady, K. A., et al. (2020). "Time-Restricted Eating Improves Glucose Tolerance in Adults with Prediabetes." Nutrition and Healthy Aging, 5(4), 352-363.
18. Wing, R. R., & Lang, W. (2020). "Weight Loss Maintenance: What Really Works?" Diabetes Care, 43(7), 1600-1607.